AAC award winners, 2001.
Peter Wilding, PhD, FACB, received his Bachelor of Science with Honors in Medical Biochemistry in 1961 and his PhD in Clinical Chemistry in 1965, both from the University of Birmingham, United Kingdom. His PhD thesis described and characterized the first case of "macro-amylasemia" and led to worldwide studies on macroenzymes. From 1965 to 1967, he was an Assistant Professor in the Department of Medicine of the University of Southern California in Los Angeles, CA. In 1967, he returned to the United Kingdom to gain further training in clinical chemistry at the Queen Elizabeth Medical Centre, Birmingham, England. From 1969 to 1972, he was Director of Pathology at the BUPA Medical Centre in London, following which he returned to Birmingham as Deputy Director of the Wolfson Research Laboratories at the University of Birmingham, where he served until he emigrated to the United States in 1977. During this period his research concentrated on the characterization of serum enzymes and the development of diagnostic methods and instruments.
From 1977 to 1982, Dr. Wilding worked with the Technicon Corporation in Tarrytown, NY as a Director of Programs and subsequently as a Vice President in the Diagnostic Systems Division. In 1982, he moved to the SmithKline Beckman Corporation in Philadelphia as Vice President of Research and Development for their Geometric Data Division. During this period, he published additional work on diagnostic methods.
Since 1986, he has been Professor of Pathology and Laboratory Medicine and Director of Clinical Chemistry at the University of Pennsylvania Medical Center, Philadelphia, PA. In this capacity he has performed functions as a clinical laboratory director, teacher, and researcher. His work has been funded by the National Cancer Institutes and industry. The research has concentrated on the development of methods for detecting malignancy and the creation of a new technology involving microfabricated devices ("microchips") for clinical analyses. This new analytical technology program has produced a series of patents and numerous publications in leading journals. This technology program has also led Dr. Wilding to play an active role in technology transfer at the University of Pennsylvania.
Dr. Wilding has served on numerous committees relating to clinical laboratory science in the United Kingdom and the United States. These committees have included several offices in AACC, including the Executive Committees of the New York Metro and Philadelphia Sections, membership of the Oak Ridge Conference Committee, Chair of the Clinical Associations Committee, membership and Chair of the Meetings Management Group, and membership of the Commission on Education and Science. He chaired the Organizing Committees for the 1991 CliniChem Meeting in Philadelphia and the 1993 National Meeting in New York City. In 1991, Dr. Wilding was elected to the Board of Directors and served as President of the Association in 1995. In addition, he served on the Finance Committee of the association and several Task Forces established by AACC.
At the international level, Dr. Wilding has been a consultant to the World Health Organization, which involved travel and lectures in several parts of the world. He was responsible for preparing the first WHO guide to laboratories operating in developing countries. He served on Expert Panels or Committees of the International Federation for Clinical Chemistry (IFCC) dealing with Reference Values, Diagnostic Products, and Analytical Quality. In addition, he served as a member and Chairman of the Education and Management Division of IFCC. He is also an Honorary Professor of the West China University of Medical Sciences in Chengdu, China.
In 1993, he received the Kone Award of the Association of Clinical Biochemists (United Kingdom) for his contributions to the field of clinical chemistry. In addition, he was awarded three Outstanding Speaker Awards by AACC and the 1989 Annual Lectureship Award of the Canadian Association of Medical Biochemists. In 1997, he was awarded Honorary Membership of the Association of Clinical Biochemists (United Kingdom) and the Roman Lectureship of the Australasian Association of Clinical Biochemistry.
Dr. Wilding is a Fellow of the Royal College of Pathologists (United Kingdom), the Royal Society of Chemistry (United Kingdom), and the National Academy of Clinical Biochemistry. He is certified by the American Board of Bioanalysis as a High Complexity Clinical Laboratory Director.
AACC Award for Outstanding Contributions through Service to the Profession of Clinical Chemistry, Sponsored by Beckman Coulter, Inc.
Stephen E. Kahn, PhD, DABCC, FACB, is presently Professor of Pathology, Cell Biology, Neurobiology, and Anatomy; Associate Director, Clinical Laboratories; Section Chief and Director, Chemistry, Toxicology, and Near Patient Testing; and Director, Core Laboratory Operations at Loyola University Medical Center (LUMC) in Maywood, IL. Dr. Kahn received a BS degree in Zoology from Michigan State University in 1972 and his PhD in Biological Chemistry from the University of Illinois Medical Center in 1979. At LUMC, he completed postdoctoral training in clinical chemistry and, in 1980, joined the Section of Clinical Chemistry as a faculty member. He became certified as a diplomate of the American Board of Clinical Chemistry (ABCC) in 1982.
An AACC member since 1979, Dr. Kahn has held numerous positions within the association at both the national and local levels. Currently, he is Chair of the Troponin I Standardization Committee as well as a member of the Nominating Committee. He is a Past-President of the Association, serving as AACC's President during AACC's 50th anniversary in 1998. During his years of service to AACC, he has served as a member-at-large of the Board of Directors as well as the Chair of the 1996 Annual Meeting Organizing Committee (AMOC), House of Delegates, Commission on Education and Scientific Affairs, Laboratory Improvement Program Management Group, Joint AACC/CAP Steering Committee, AMOC Proficiency Testing Task Force, and Meetings Task Force. He has served two terms as a member of the Finance Committee; he has also served as a member on five AACC Task Forces, including the Task Group on Journal Operations, on four AMOCs, and on several other committees. In the Chicago Section of AACC, Dr. Kahn has held many positions, including Section Chair, Program Chair, and for 6 years, Section Delegate. He is currently a member of the Critical Care Testing, Point of Care Testing, and Therapeutic Drug Monitoring/Clinical Toxicology Divisions of AACC.
Dr. Kahn served as a member of the Board of Directors of the ABCC, including a 4-year term as ABCC's Secretary-Treasurer. He has been active on a local or national level in serving for the Clinical Laboratory Management Association and American Medical Association, as well as the National Committee for Clinical Laboratory Standards. He is a fellow of the National Academy of Clinical Biochemistry (NACB) and is currently serving a second term as a member of NACB's Nominating Committee. Dr. Kahn is also currently a member of the Practice Analysis Task Force of the American Society of Clinical Pathologists.
Among the awards that Dr. Kahn has received are the AACC Chicago Sections Samuel L. Natelson Award for outstanding contributions as a senior investigator as well as the Albert A. Dietz Award for outstanding contributions in service. He is a recipient of AACC's Past-President Award and received presidential citations from AACC Past-Presidents K. Michael Parker and Frank Sedor. Dr. Kahn is also very committed to education and has approximately 100 published articles, chapters, and abstracts. He has given numerous invited presentations on many topics throughout the United States. His current areas of professional interest are protein markers of tissue injury, laboratory utilization, critical care, and near-patient testing.
AACC Award for Outstanding Contributions in Education, Sponsored by Quest Diagnostics Incorporated
Lawrence M. Silverman, PhD, DABCC, DABMG, is Director of the Division of Molecular Pathology as well as Professor of Pathology and Laboratory Medicine and of Genetics and Molecular Biology at the University of North Carolina School of Medicine in Chapel Hill, NC. In addition, he is Director of the Molecular Genetics Laboratory and Associate Director of the Clinical Chemistry Laboratories at the University of North Carolina Hospitals and Director of the American Board of Medical Genetics (ABMG) postdoctoral training program in Clinical Molecular Genetics. He received his BA in Chemistry from Washington and Jefferson College in Washington, PA. After 2 years in the United States Army, he received his PhD in Physiological Chemistry followed by a postdoctoral fellowship in Clinical Chemistry, both under Hanns-Dieter Gruemer, MD, at the Ohio State University. After serving as Clinical Chemist at the Hospital of the Good Samaritan in Los Angeles, where he was also Clinical Assistant Professor at the University of Southern California, Dr. Silverman moved to Chapel Hill.
Dr. Silverman has been active in the Ohio Valley, Southern California, and North Carolina sections of the AACC and has served in numerous capacities, including councillor, Secretary-Treasurer, as a member of the nominating committee, and Chair. He was instrumental in establishing the AACC Division of Molecular Pathology in 1989. He served on the Board of Editors for Clinical Chemistry from 1990 to 1999, the last 5 years as Reviews Co-Editor; the Board of Editors for the Yearbook of Pathology and Clinical Pathology (1986-1991); and is currently on the Board of Editors for Clinica Chimica Acta and on the Editorial Advisory Board for Strategies for Clinical Chemistry. He has served as Vice-President and Chair of Program Evaluations for the Commission on Accreditation in Clinical Chemistry (ComAcc) since 1989, as Vice-President and Chair, Credentials Committee of the ABCC since 1996, and is currently Chair of the Molecular Diagnostics Exam committee. He was Co-Chair of the Beckman Symposium on Nucleic Acids (1989) and Co-Chair of Symposia for the AACC National Meeting in 1991. He currently serves on the Clinical Laboratory Improvement Advisory Committee (CLIAC), which provides scientific and technical advice to the Secretary, Department of Health and Human Services, and the Director of the CDC, and is Chair of the Working Group on Molecular Genetic Testing. He also serves as a consultant to the Food and Drug Administration (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee and is a member of the FDA Professional Roundtable on Genetic Testing. Among the awards Dr. Silverman has received are (a) the Phil Blatt Award for pathology resident teaching at the University of North Carolina, (b) the ISCABER Research Award from Ohio State University for graduate research, (c) the Miriam Reiner Award from the Capital Section of the AACC for contributions to the field of clinical chemistry, and (d) the inaugural AACC Young Investigator Award.
In addition to training 12 clinical molecular genetic fellows as director of the ABMG training program, Dr. Silverman has had a major role in training 14 fellows during his 15-year tenure as director and co-director of the clinical chemistry postdoctoral fellowship program at the University of North Carolina. Four fellows have been recipients of the AACC Young Investigator Award. Dr. Silverman s research has focused on basic and clinical aspects of molecular genetics, particularly cystic fibrosis, Duchenne muscular dystrophy, and hereditary breast/ovarian cancer. He has been Principal Investigator on 13 research grants focused on these disorders. He has authored 91 original scientific papers, more than 100 abstracts, 27 book chapters, and coedited, with Ruth Heim, Molecular Pathology: Approaches to Diagnosing Human Disease in the Clinical Laboratory, published in 1994. His proudest accomplishment is that his coauthors and collaborators on these endeavors have primarily been fellows and graduate students.
AACC Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research
Dr. Larry J. Kricka, President of the American Association for Clinical Chemistry, recently announced that the Awards Committee has selected James L. Wittliff, PhD, FACB, distinguished investigator at the University of Louisville, as the recipient of the award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research. Dr. Wittliff received an undergraduate degree in Chemistry and a PhD degree in Molecular Biology from the University of Texas at Austin, and a MS degree in Biochemistry at Louisiana State University, School of Medicine. His postdoctoral studies were conducted in the Biology Division of Oak Ridge National Laboratory in Tennessee. Before joining the University of Louisville in 1976 as Professor and Chairman of the Department of Biochemistry, he assisted in the development of the Cancer Center at the University of Rochester, where he was Director of the Section on Endocrine Biochemistry and a member of the Department of Biochemistry.
Dr. Wittliff and his research team are internationally recognized for innovative studies on the molecular mechanisms by which estrogens promote signal transduction in healthy tissue and breast cancer. He was one of the first investigators to identify a correlation between the presence of estrogen receptor proteins in a breast cancer biopsy and response to either additive or surgical ablative hormone therapy. This finding contributed significantly to collaborative studies with the National Surgical Adjuvant Breast Project (NSABP), which established the use of Tamoxifen as an adjuvant therapy for breast cancer. His results also helped extend the use of estrogen and progestin receptors as tissue markers of a breast cancer patient's prognosis. Dr. Wittliff's discovery of frequent receptor polymorphism in human breast cancer led to the prediction of the presence of another isoform of the estrogen receptor, confirmed recently as ERbeta.
A major contribution to laboratory medicine was made when Dr. Wittliff, working with NEN/DuPont, developed the first FDA-approved kits for assessing steroid receptor concentrations in tumor biopsies. Complementing this effort, Dr. Wittliff's laboratory in the James Graham Brown Cancer Center, University of Louisville, was designated the National Reference Facility for performing quality assurance surveys of receptor testing for cooperative clinical trial groups in the United States and Canada. His laboratory continues to serve the profession by collaborating with the College of American Pathologists in providing proficiency surveys for these analytes.
Dr. Wittliff's laboratory has provided comprehensive graduate training in molecular endocrinology for more than three decades, and the International Scholars Program he founded in 1969 has attracted more than 75 research scientists and students from 31 countries. He and his research fellows have published several hundred scientific papers and book chapters on steroid and peptide hormone receptors, covering both basic and clinical aspects. In addition to numerous professorships at universities in Europe, Asia, and Africa, he was a recipient of the George Grannis Research Award and elected a Fellow of the NACB in 1984. Dr. Wittliff and Rosalyn Yalow (Nobel Laureate) received the Distinguished Scientist Awards from the Clinical Ligand Assay Society in 1988. Dr. Wittliff was appointed Inaugural Guest Professor at the Institute of Applied Microbiology in Vienna, Austria in 1992, where he continues to serve as Visiting Professor in addition to his duties as Director of the Hormone Receptor Laboratory in the Brown Cancer Center. He was elected President of the International Clinical Ligand Assay Society in 1996.
In recognition of his research and clinical contributions to the biology and treatment of cancer, the University of Innsbruck, Austria awarded Dr. Wittliff the degree, Doctor of Medicine honoris causa in 1998. Currently, Dr. Wittliff is serving as Visiting Industry Professor at Arcturus Applied Genomics in San Diego, where he is conducting research on the gene expression profiles of healthy and neoplastic cells procured by a novel technology called Laser Capture Microdissection.
AACC Award for Outstanding Scientific Achievements by a Young Investigator, Sponsored by Roche Diagnostics Corp.
Lynn Bry, MD, PhD, is a clinical fellow in pathology at Brigham & Women's Hospital at Harvard Medical School in Boston, MA. She received her Bachelor's degree in Genetics and Development from Cornell University in 1990, then entered the Medical Scientist Training Program at Washington University Medical School in St. Louis. She did her thesis work in the laboratory of Dr. Jeffrey I. Gordon and developed two novel systems for studying host-microbial cross-talk within the gastrointestinal tract. She was awarded her MD and a PhD in Molecular Microbiology and Pathogenesis in 1998. She subsequently entered the residency program in laboratory medicine at Brigham & Women's Hospital. While in her second year of the residency program, she was awarded a Howard Hughes Research Fellowship for Physicians to pursue a postdoctoral fellowship in molecular immunology in the laboratory of Dr. Michael B. Brenner at Brigham & Women's Hospital. Her research currently involves the study of lymphocyte-epithelial cross-talk in the small intestine and colon.
While at Washington University, Dr. Bry also founded and continues to direct MadSci Network (www. madsci.org; formerly the MAD Scientist Network), an Ask-A-Scientist service based on the World Wide Web. The service involves more than 900 globally situated volunteer scientists who field questions from the general public and from students in kindergarten through the 12th grade. Last year the service received more than 32 000 questions in subjects from astronomy to zoology. The site was nominated for a Webby 2000 Award in science, and has been named one of the top 50 science sites on the web by Popular Science magazine for the past 3 years. Dr. Bry has been a consultant to the United States Department of Education concerning the use of the Internet for science education and has spoken before members of the Office of Science & Technology Policy and the United States Library of Congress concerning the establishment of distributed expert systems.
Dr. Bry has authored numerous publications, including an original paper in Science detailing a molecular model of host-microbial cross-talk in the small intestine. She recently authored a review article in Clinical Chemistry with David Sacks, MB, ChB, and Philip Chen, MD, PhD, also from Brigham & Women's Hospital, concerning the effects of variant hemoglobin's on testing for glycated hemoglobins. She currently is involved in efforts at Brigham & Women's Hospital to develop a comprehensive specimen banking system and has a long-standing interest in developing web-based means for providing access to laboratory data and functions.
In addition to serving as director of MadSci Network, Dr. Bry also maintains the "Surrealism Server" and is a member of the online arts group SITO (www.sito.org). As a former member of the Cornell women's crew team, she continues to participate in the sport of rowing. She is also a member of the Massachusetts Institute of Technology Nautical Association and enjoys sailing in the Boston area during the summer months.
AACC International Travel Fellowship, Sponsored by BD Vacutainer Systems, Preanalytical Solutions of Becton Dickinson and Company
Bernard Gouget, PhD, is Coordinator, Medical Expertise, French Hospital Federation (the FHF is a national organization representing public hospitals) and Assistant Professor of Medical Physiology, University of Paris V.
Dr Gouget has pursued a career in laboratory medicine with two main thrusts: organ physiology in intensive care and the adaptation of laboratory services to required standards of patient care. After his initial studies in laboratory medicine, he worked in the Paris public hospital service in the Necker Children's' Hospital, becoming Section Head in the critical care laboratory. At the same time, he continued studies that led to a doctorate in economic sciences and certification in hospital management. This combination of interests has provided Dr. Gouget with an exceptional experience in France, which he has extended to encompass many countries around the world.
The interest in organ physiology in critical care is demonstrated by his activities in the fields of critical care analysis and the applications of micro- and nanotechnologies to existing and new parameters of organ function. An active member of the French Society of Clinical Chemistry's Expert Panel on pH and Blood Gas Analysis, he has participated in numerous reviews and recommendations concerning technologies and organizational solutions for critical care testing, and has coordinated several multicenter trials of new products.
Dr. Gouget later served as Deputy Director of the clinical laboratory at a regional hospital in Meaux, near Paris. This was a pioneering institution in the 1990s and a testing center for several innovative technologies for diagnosis and management, notably imaging techniques, all of which had profound implications for the role of the clinical laboratory.
Returning to Paris in 1992, Dr. Gouget directed the activities of monitoring new technologies and commercial developments for the National Center for Hospital Expertise (CNEH) and set up the CNEH Laboratory Services Club, a unique working group composed of members of the laboratory professions, hospital managers, and representatives from industry, whose role was to proactively examine the organizational and economic impact of the clinical laboratory in the hospital service and to evaluate the practical solutions that were used in other countries for the applicability in a French context.
Dr. Gouget also contributed largely to the development of a database on laboratory performance, both activities and costs, that allowed participating laboratories an opportunity for benchmarking, and to the laboratory aspects of hospital accreditation in the first manual for accreditation of French Public Hospitals in 1993. As Manager and Coordinator for Laboratory Projects at the CNEH, he performed more than 60 audits of laboratories, including audits for planning laboratory consolidation projects in public and teaching hospitals.
Following an internal mission for the Medical Policy Directorate of the Headquarters of the Paris Public Hospitals, which involved the planning of technical services for a region of 13 million people, he joined the French Hospital Federation in 2000 as Coordinator and Manager of teams of experts in various medical disciplines. Their role is strategic, to reflect on the impact on hospital organizations arising from changes in social and healthcare policies as well as new technologies. Dr. Gouget's personal interests are especially oriented toward evaluating the impact of new diagnostic and therapeutic techniques, including information technologies and telecommunications, on the way hospitals are organized and on the new types of professional responsibilities that will arise, including those in the laboratory.
Since the early 1990s, Dr. Gouget has been active in the IFCC. Currently, he is Chair of the Communications and Publications Division (IFCC-CPD). In this context, he has initiated and overseen numerous changes, notably in the use of the IFCC website for communication between National Societies, Working Groups, and the membership. He foresees the IFCC-CPD ultimately putting in place interactive networks for training and knowledge management for the membership.
Dr. Gouget is especially concerned with the needs of regional organizations and members in IFCC, being active in the promotion of the IberoAmerican activities and contributing to professional advancement in Latin America and Mexico. He feels very honored by the award and plans to use it to extend the network of contacts he has already made into new territories through participation in congresses and workshops in India, Eastern Europe, and Mediterranean countries.
The AACC Lectureship Award, Supported by an Educational Grant from Bayer Diagnostics
W. French Anderson, MD, has had a distinguished career in which he has made significant advances in mammalian gene expression and gene transfer as a prelude to his pioneering work in initiating human gene therapy. His first major contribution was the discovery, isolation, and purification of the initiation factors required for the synthesis of proteins in mammalian cells (Nature 1970;226:511-4). His second important advance was the isolation and characterization of hemoglobin messenger RNA from patients with thalassemia and with sickle cell anemia. Dr. Anderson also demonstrated that the molecular defect in these diseases could be reproduced in the test tube, using human mRNA in a rabbit cell-free protein synthesizing system. The initial report of this work (J Clin Invest 1971;50:2458-60) describes the first successful application of molecular biology in isolating the genetic molecule (the mRNA) responsible for a human disease. Anderson and his colleagues then sought to identify the regulatory mechanisms that control the synthesis of hemoglobin mRNA and were the first to demonstrate that gene-specific regulatory factors exist for hemoglobin gene expression (Nature 1979;277:534-8).
Dr. Anderson and the late Dr. Elaine Diacumakos developed the technique of physical microinjection for inserting cloned genes into the nuclei of living mammalian cells (Proc Natl Acad Sci U S A 1980;77: 5399-403). This microinjection procedure was subsequently used by Gordon and Ruddle to develop transgenic mice. Because the microinjection procedure could not be used to efficiently insert genes into bone marrow cells, Anderson and Dr. Eli Gilboa developed retroviral vectors that provided efficient gene transfer. In 1984, Dr. Anderson concluded in a highly quoted review (Science 1984;226:401-9) that retroviral vectors were the way to carry out human gene therapy and that adenosine deaminase (ADA) deficiency was the best initial prospect for gene therapy. He and Dr. Gilboa engineered a series of vectors that could be used for gene transfer in vivo (Science 1985;230:1395-8). One of these vectors, containing the human ADA gene, was successfully used to correct the ADA deficiency of defective T and B cells from ADA(-) patients in vitro (Proc Natl Acad Sci U S A 1986;83: 6563-7). An autologous bone marrow transplantation/ gene transfer protocol was then established in monkeys. Expression of the human ADA gene in the bloodstream of several primates was demonstrated (J Exp Med 1987;166:219-34).
Dr. Anderson then collaborated with Drs. Steven Rosenberg and Michael Blaese, NCI, NIH, to carry out the first approved human gene transfer/therapy clinical protocols. In the first protocol, a marker gene was used to help study a form of cancer therapy called adoptive immunotherapy. This study showed that gene transfer was safe and could be used to answer important scientific/ clinical questions in patients (N Engl J Med 1990; 323:570-8).
The first human gene therapy protocol was begun September 14, 1990. A 4-year-old girl with a genetic disease called severe combined immunodeficiency (SCID) caused by the absence of ADA was treated. T lymphocytes were removed from the patient at intervals of one to several months, a normal ADA gene was inserted into these lymphocytes via gene transfer, and the gene-corrected cells were returned to her body (Science 1995;270:475-80). Her immune system gradually returned to normal, and she has led an essentially normal life for the past 9 years. The success of this experiment has led to the emergence of the field of human gene therapy.
In collaboration with Dr. Esmail Zanjani, Dr. Anderson has explored the possibility of in utero gene therapy to correct genetic defects that cause irreversible damage before birth. Early studies used ex vivo gene transfer into hematopoietic stem cells (Blood 1989;73:1066-73), but more recent studies have demonstrated the success of direct vector injection into the fetus (Hum Gene Ther 1998;99: 1571-85). Recently, Drs. Zanjani and Anderson reviewed this exciting but controversial new field (Science 1999; 285:2084-8).
Dr. Anderson's other major scientific interest at present is the development of retroviral vectors that can target specific cell types. His laboratory has carried out a systemic evaluation of the receptor-binding region of the envelope protein of the murine retrovirus used in human gene therapy clinical protocols (J Virol 1996;70: 1768-74). They have demonstrated the molecular block in direct receptor-binding-domain substitution (Proc Natl Acad Sci U S A 1999;96: 4005-10), but the success of using a modified approach (Hum Gene Ther 1997;8:2183-92).
Finally, Dr. Anderson has provided definitive reviews of the field of human gene therapy over a period of 20 years [major reviews in addition to the ones already listed: Science 1992;256:808-13 and Nature 1998; 392(Suppl): 25-30].
The Sigi Ziering Award for Outstanding Contribution for a Publication in the Journal Clinical Chemistry, Sponsored by Diagnostic Products Corporation (DPC)
Michel G. Bergeron, MD, was born in Quebec City, Canada, where he completed his college studies and received his MD in 1968 from Laval University. He did his Specialty Training in Internal Medicine at McGill University in Montreal. Following this, Dr Bergeron went to Boston to complete his training in infectious diseases and microbiology with Dr. Louis Weinstein at Tufts University, and at the Massachusetts Institute of Technology where he worked with Dr. Salvador Luria, a Nobel Laureate. Dr. Bergeron returned to Quebec in 1974 and founded the Infectious Diseases Research Centre at the University Hospital of Laval University in Quebec City. Today, the Centre is composed of 225 researchers, making it one of the largest infectious disease research centers in North America.
Dr. Bergeron is the author or coauthor of more than 300 scientific publications and has given more than 500 presentations of his work at different universities and international meetings. His research is focused on the development of rapid (<1 h) DNA-based tests to identify microorganisms responsible for infectious diseases. These tests, he hopes, will revolutionize the clinical management of infectious diseases and reduce antimicrobial resistance.
Dr. Bergeron has received many awards and honors during his career, including being named Fellow of the Infectious Disease Society of America in 1980 and Professeur des Universites de France in 1987-1988, a title designated by President Francois Mitterand and INSERMS of France. Dr. Bergeron s most recent awards are the Prix Louis Pasteur from the Association des M6decins Microbiologistes-infectiologues du Quebec in 1998 and, in 2000, the Emeritas Physicians Medal, which was given to the 20 Quebec-based physicians who have had the most significant impact on medicine in the last 20 years. He has also won the Canadian 2000 MEDEC Award for medical achievement. Dr. Bergeron has been President of three Canadian professional societies, the Canadian Infectious Disease Society (CIDS), the Canadian Association of Medical Microbiologists (CAMM), and the Canadian Society for Clinical Investigation (CSCI), as well as the InterAmerican Society of Chemotherapy. He has chaired multiple international conferences, the most remarkable being the International Congress of Chemotherapy in 1995 in Montreal, which was attended by more than 8000 people from 97 countries. He is on the editorial board of seven international journals and Chairman of the Board of the Canadian Foundation Louis Pasteur. He continues to teach at Laval University to students, postgraduate, and fellows, and has trained more than 70 graduate and postgraduate students. Dr. Bergeron was actively involved in the establishment of the Canadian Institutes of Health Research, which started its activities in 2000, in replacement of the Medical Research Council of Canada (MRC). He is also a member of the Science Advisory Board of Health Canada, established by Federal Health Minister Allan Rock, and of the Advisory Board of the Institute of Infection and Immunity.
Dr. Bergeron founded Infectio Diagnostic (IDI) Inc. in 1995 and currently is the company's Chairman of the Board. The company intends to introduce in 2001 the first of a series of rapid innovative DNA-based diagnostic tests developed by Dr. Bergeron and his research team at Laval University. These tests, now manufactured by IDI in Quebec city, will provide the identification of microbes in less than 1 h compared with the current standard culture, which takes 2 to 3 days. This technology is a true revolution because it is the fastest DNA-based test in the world today.
AACC's Past-President's Award, Sponsored by Allegiance Healthcare Corporation, a Cardinal Health Company
Frank A. Sedor, PhD, DABCC, is presently Administrative Director for the Carl Core Laboratory, Blood Gas Laboratory, and Clinical Pediatric Laboratory as well as Director for Clinical Chemistry, TDM, and Toxicology Services at Duke University Medical Center, Durham, NC. He is also a faculty member of The Department of Pathology, Duke University. Dr. Sedor earned a BA degree in Chemistry from Wabash College in 1966 and his PhD in Bioinorganic Chemistry from the University of Florida (U of F) in 1971. After postdoctoral training in Biochemistry (U of F), he completed a postdoctoral fellowship in Clinical Chemistry at The University of North Carolina (Chapel Hill). He joined the Department of Pathology and the Section of Clinical Chemistry as a faculty member at Duke University in 1978. He became a certified Diplomate of the ABCC in 1979.
An AACC member since 1977, Dr. Sedor has held numerous positions within the Association at the local and national levels. Dr. Sedor continues as a member of AACC's Board of Directors and the Board Executive Committee, where he presently serves as the immediate Past-President, having the honor of serving as the AACC's 51st President in the year 2000. He currently also serves as Chair of the Executive Management Team of Clinical Chemistry. Among his past AACC responsibilities, Dr. Sedor was Co-Chair of the 1991 Annual Meeting Organizing Committee and Chair of the 1997 AMOC. Previously Dr. Sedor chaired the AACC Council, the Ad Hoc Committee to Reorganize Council, the Commission on Education and Scientific Affairs, the Meetings Management Group, the Divisions Management Group, the AACC Research Committee, and more recently, the Program Coordinating Committee. He is in his fourth term as a member of the Finance Committee. He has also served as Chair of the AACC Committee on Training and Certification, on the President's Committee to Define Standards of Practice, as an advisor to the Health Care Financing Administration (HCFA) Medical Review Panel developing the ICD-10 PCS system, to the HCFA Uniform Data Set System Project Review, and as representative to the HCFA-AMA Consensus Conference on Laboratory Utilization. In the North Carolina section, Dr. Sedor has held every office, including Secretary-Treasurer, Program Chair, Chair, and Councilor at Large to the AACC Council. Dr. Sedor is a member of the Fetal-Maternal Medicine Division.
A staunch believer in investing one's self in his profession, Dr. Sedor continues efforts in teaching and research in the areas of laboratory utilization and pediatric and maternal diagnostic tools. He also is director of the postdoctoral training program at Duke University Medical Center. His efforts to ensure the integrity of the profession continue as he serves as AACC representative to the ABCC. He had previously served as President, ABCC, and Chair, Credentials Committee while on the board of ABCC. He has also served on the board of the NACB and as an invited reviewer for the journals Clinical Chemistry, Archives of Pathology and Laboratory Medicine, American Heart Journal, and Intensive Care Journal.
William C. Butts, 1942-2001
William C. Butts, PhD, passed away on January 18, 2001. Bill was born on January 13, 1942, in Evanston, IL. In 1959, he received a Bachelor of Science degree in Chemistry from Purdue University. In 1968, he obtained a PhD in Analytical Chemistry from Iowa State University. Later he had postdoctoral training in Alex Kaplan s training program at the University of Washington.
Bill spent his entire career in the fields of chemistry and clinical chemistry, first at the Oak Ridge National Laboratory in Tennessee, then at the Institute of Health Research in San Francisco, and for the last 26 years at Group Health Cooperative in Seattle where he held the position of Director of Laboratory Services.
Bill joined the American Association for Clinical Chemistry in 1972 and became very active in the affairs of the Association at both the local and national levels, especially in the area of meeting management. For example, in 1990 he chaired the contributed papers subcommittee of the Organizing Committee of the joint AACC National meeting and 14th International Congress of Clinical Chemistry. In 1995, he cochaired the Organizing Committee for the AACC Annual meeting. In 1998, he served as the Abstracts Coordinator for the Organizing Committee of the AACC annual meeting. Working with Bill was a delight because he accepted responsibility readily, performed his duties in his usual quiet and efficient manner, and was always ready to lend a helping hand when necessary.
In addition to science and clinical chemistry, Bill had many other interests, including golf, tennis, travel, gardening, astronomy, and bridge. He was also a gourmet chef, and I particularly remember one memorable meal in Oak Ridge where Bill produced several dishes that featured fresh mushrooms that were grown locally.
Bill is survived by his wife, Dotty; his sons, David and Brian; a brother, Robert Butts; and his father, C.L. Butts.
With his passing, our profession has lost a worthy participant, we a trusted colleague, and many of us a valued friend.
In honor of Bill, a scholarship fund has been established through Group Health. Memorials may be made in Bill's name to: Group Health Community Foundation, Dept. 4194, PO Box 34936, Seattle, WA 98124-1936, Attn: William C. Butts, PhD, Memorial Scholarship Fund.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||The Clinical Chemist|
|Date:||Jul 1, 2001|
|Previous Article:||Amino Acid Analysis Protocols.|
|Next Article:||Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.|